CN1149722A - Multiple liquid quality control pig serum and preparing method - Google Patents
Multiple liquid quality control pig serum and preparing method Download PDFInfo
- Publication number
- CN1149722A CN1149722A CN 95117435 CN95117435A CN1149722A CN 1149722 A CN1149722 A CN 1149722A CN 95117435 CN95117435 CN 95117435 CN 95117435 A CN95117435 A CN 95117435A CN 1149722 A CN1149722 A CN 1149722A
- Authority
- CN
- China
- Prior art keywords
- mol
- serum
- multiple liquid
- quality control
- liquid quality
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The present invention uses fresh pig's blood as raw material and the pig serum is made up through separating, freezing, component regulating and adding glycol as stabilizer. The invented product contains multiple components for quality control of serum and overcomes the error for subpackage and redissolving of frozen dried serum.
Description
The technical field of the invention is the medical test quality control, specifically multiple liquid quality control pig serum and preparation method.
The employed quality controling serum overwhelming majority is the freeze-drying porcine blood serum on the present domestic medical test.This serum exists and redissolves error when the packing sum of errors uses before the inevitable freeze-drying.Stable inadequately to some enzyme preservation, but also exist production equipment costliness, shortcomings such as complex process.The composition of present employed freeze-drying porcine blood serum of while is ten remainders only, can not satisfy the needs of medical test development far away.
The objective of the invention is to replace present freeze-dry blood serum for society provides multiple liquid Quality Control porcine blood serum.
Technical scheme of the present invention is, uses wide material sources, and the higher pig blood of enzyme content is raw material, adds various required compositions.Make the multiple liquid Quality Control porcine blood serum that meets the Quality Control requirement with analyzing pure ethylene glycol used as stabilizers and antiseptic.
Concrete technology is:
1, gathers pig blood;
2, separation of serum;
3, each Quality Control component content in the serum analysis;
4 adjustment are respectively analyzed composition and are made into quality controlled serum;
5, filtration, packing, label.
The multiple liquid quality control pig serum for preparing contains following composition and content:
GLU1-30mmol/L, BUN2-40mmol/L, CRE50-1000 μ mol/L, UA50-2000 μ mol/L, TBIL5-3000 μ mol/L, CHO2-60mmol/L, Ca (Cacl
2, 2H
2O) 1-5mmol/L, P (NaH
2PO
4, 2H
2O) 0.5-3mmol/L, Mg (Mgcl
2, 6H
2O) 0.3-5mmol/L, CL (Nacl) 50-150mmol/L, K (Kcl) 2-10mmol/L, Na (CH
3CooNa) 50-200mmol/L, Co
2(NaHco
3) 10-50mmol/L, TG0.2-5mmol/L, GOT20-1000U/L, GPT20-1000U/L, LDH50-1500U/L, HBDH50-1500U/L, CK50-1500U/L, AMY50-2000U/L, AKP30-1000U/L, γ-GT20-1000U/L, ALB20-80g/L, TP20-100g/L, DBIL1-50umol/L, Fe2-50 μ mol/L, bile acid 3-50umol/L, IgG4-40g/L, IgA0.3-6g/L, IgM0.2-5g/L, C
30.1-3g/L, C
40.02-1g/L, APOA
10.5-5g/L, APOB0.5-5g/L, HDL-C0.5-13mmol/L, lithium 1-5mmol/L, other blood medicines of theophylline 50-500 μ mol/L: 10.
Advantage of the present invention is:
1, compares with the freeze-dry blood serum of present use, do not have the error of packing and redissolution.
2, owing to contain stabilizing agent in the serum, various analysis ingredient stabilities especially are easy to the enzyme that changes in the serum.
3, production technology is simple, does not need expensive specialized equipment.
Embodiment:
With preparation intermediate value multiple liquid quality control pig serum is example.
1, gathers pig blood: collect 5000 milliliters of free of contamination fresh pig blood in the slaughterhouse, treat to transport the laboratory back after the natural coagulation.
2, separation of serum: collect and solidified pig blood supernatant, separate, discarded the type composition through hydro-extractor.The serum of separator well is reserved detection sample postposition-30 ℃ low temperature refrigerator 24 hours, take out the room temperature fusing, freeze repeatedly molten twice.
3, each Quality Control component content in the serum analysis: analytical approach is measured the content of each Quality Control composition in the serum routinely.
4, adjusting is respectively analyzed composition and is made into the multiple liquid quality controling serum: according to the quality controlled serum requirement, on the basis of former each composition of serum, add respective substance, make it to reach requirement concentration, add the stabilizing agent-ethylene glycol (analyzing pure) of quality controlled serum total amount 1/3rd, make satisfactory quality controlled serum.
It is as follows to add step:
(1) adding of enzyme:
Enzyme content is very high in the porcine blood serum, does not generally need to add in addition the enzyme composition, only just need add the enzyme composition when preparation high value quality controlled serum.Can prepare various enzymes voluntarily, just can add after slightly carrying, needn't purifying.Wherein, GOT and GPT can extract from Pigs Hearts; It is the easiest that AMY adds people's saliva; CK can extract from muscle; AKP can extract from people's placenta; γ-GT can extract from the pig kidney.The said extracted technology is known technology.
(2) adding of albumen:
From unnecessary porcine blood serum, extract albuminous and globulin respectively with the sulfate of ammoniac salting out method, join in the quality controlled serum.
(3) adding of other compositions:
Enzyme and the adjusted serum of albumen are remeasured volume, unnecessary part is sopped up with the dried glue of polyacrylamide that contains propionyl acid 70g/L.According to the content that determines other compositions, calculate the amount that needs adding, join in the serum one by one.Wherein:
The adding method of a, TBIL (cholerythrin): the cholerythrin powder after will weighing is poured the band glass stopper in vitro, adds 0.1MNaOH5.5 milliliter vibration dissolving, mixes with serum immediately, pours in the total serum then.
The adding method of b, UA (uric acid): the uric acid after will weighing adds in 10 ml waters of 60 ℃ of pre-temperature, adds IMNaOH0.7ml, and the limit edged is shake, and this lysate is added in the total serum immediately,
(4) adding of ethylene glycol:
In above-mentioned 1 liter of serum, add 0.5 liter and analyze pure ethylene glycol, be mixed, just obtain 1.5 liters of quality controlled serums.
(5) filtration, packing, label:
The quality controlled serum that the prepares filter membrane device with 0.2 μ m is filtered, be divided in then in 10 milliliters the brown vial, adorn 3 milliliters for every.Post label.
The intermediate value multiple liquid quality control pig serum for preparing contains following composition and content: GLU5.6mmol/L, 3UN6.0mmol/L, CRE110 μ mol/L, UA400 μ mol/L, TBIL34 μ mol/L, CHO6.0mmol/L, Ca (Cacl
22H
2O) 2.5mmol/L, P1.5mmol/L, Mg1.0mmol/L, CL105mmol/L, K5.0mmol/L, Na (CH
3CooNa) 140mmol/L, Co
2(NaHCO
328mmol/L, TG0.54mmol/L, GOT132u/L, GPT52u/L, LDH750u/L, HBDH552u/L, CK373u/L, AMY832u/L, AKP56u/L, γ-GT30u/L, ALB45g/L, TP70g/L, DBIL6umol/L, Fe25 μ mol/L, bile acid 10umol/L, IgG8g/L, IgA1g/L, IgM1g/L, C
31g/L, C
40.2g/L, APOA
11.5g/L, APOB1.0g/L, HDL-C1.5mmol/L, lithium 2.0mmol/L, other blood medicines of theophylline 110 μ mol/L: 10.
Claims (4)
1, a kind of multiple liquid quality control pig serum, it is characterized by: it contains ethylene glycol, also contains routine composition and content down.
GLU1-30mmol/L, BUN2-40mmol/L, CRE50-1000 μ mol/L, UA50-2000 μ mol/L, TBIL5-3000 μ mol/L, CHO2-60mmol/L, Ca1-5mmol/L, P0.5-3mmol/L, Mg0.3-5mmol/L, CL50-150mmol/L, K2-10mmol/L, Na50-200mmol/L, Co
210-50mmol/L, TG0.2-5mmol/L, GOT20-1000U/L, GPT20-1000U/L, LDH50-1500U/L, HBDH50-1500U/L, CK50-1500U/L, AMY50-2000U/L, AKP30-1000U/L, γ-GT20-1000U/L, ALB20-80g/L, TP20-100g/L, DBIL1-50umol/L, Fe2-50 μ mol/L, bile acid 3-50umol/L, IgG4-40g/L, IgA0.3-6g/L, IgM0.2-5g/L, C
30.1-3g/L, C
40.02-1g/L, APOA
10.5-5g/L, APOB0.5-5g/L, HDL-C0.5-13mmol/L, lithium 1-5mmol/L, other blood medicines of theophylline 50-500 μ mol/L: 10.
2, a kind of multiple liquid quality control pig serum as claimed in claim 1 is characterized by, and glycol content is 1/3rd of a quality controlled serum total amount.
3, a kind of multiple liquid quality control pig serum as claimed in claim 1 is characterized by, and the content of each composition of intermediate value multiple liquid quality controling serum is:
GLU5.6mmol/L, BUN6.0mmol/L, CRE110 μ mol/L, UA400 μ mol/L, TBIL34 μ mol/L, CBO6.0mmol/L, Ca2.5mmol/L, P1.5mmol/L, Mg1.0mmol/L, CL105mmol/L, K5.0mmol/L, Na140mmol/L, Co
228mmol/L, TG0.54mmol/L, GOT132u/L, GPT52u/L, LDH750u/L, HBDH552u/L, CK373u/L, AMY832u/L, AKP56u/L, γ-GT30u/L, ALB45g/L, TP70g/L, DBIL6umol/L, Fe25 μ mol/L, bile acid 10umol/L, IgG8g/L, IgAlg/L, IgMlg/L, C
3Lg/L, C
40.2g/L, APOA
11.5g/L, APOB1.0g/L, HDL-C1.5mmol/L, lithium 2.0mmol/L, other blood medicines of theophylline 110 μ mol/L: 10.
4, a kind of method for preparing the multiple liquid quality controling serum comprises and gathers pig blood, precipitation, separation, freezing, dissolving, it is characterized by, and needs to add ethylene glycol and each special quality control composition in preparation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 95117435 CN1054205C (en) | 1995-11-09 | 1995-11-09 | Multiple liquid quality control pig serum and preparing method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 95117435 CN1054205C (en) | 1995-11-09 | 1995-11-09 | Multiple liquid quality control pig serum and preparing method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1149722A true CN1149722A (en) | 1997-05-14 |
CN1054205C CN1054205C (en) | 2000-07-05 |
Family
ID=5081226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 95117435 Expired - Fee Related CN1054205C (en) | 1995-11-09 | 1995-11-09 | Multiple liquid quality control pig serum and preparing method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1054205C (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1067551C (en) * | 1998-01-04 | 2001-06-27 | 刘荣秀 | Preparation of high-immunity pig-sourced serum resisting main infectious diseases of chicken |
CN100541201C (en) * | 2005-02-01 | 2009-09-16 | 上海市血液中心 | The dilution mother liquor of glutamic-pyruvic transaminase quality control product |
CN101762710A (en) * | 2010-01-26 | 2010-06-30 | 明德松 | Multinomial liquid quality control material and preparation method thereof |
CN101930009A (en) * | 2009-11-19 | 2010-12-29 | 首都医科大学附属北京朝阳医院 | Serum calcium standard substance |
CN104062442A (en) * | 2014-07-02 | 2014-09-24 | 明德松 | Liquid quality control material with multiple autoantibodies and preparation method thereof |
CN108152519A (en) * | 2017-11-06 | 2018-06-12 | 宁波美康保生生物医学工程有限公司 | For the preparation method of the blood plasma quality-control product of centrifugal type microfludic chip quality control |
CN113959807A (en) * | 2021-10-26 | 2022-01-21 | 上海瀚诺威生物科技有限公司 | Preparation method of glycosylated hemoglobin calibration quality control product |
-
1995
- 1995-11-09 CN CN 95117435 patent/CN1054205C/en not_active Expired - Fee Related
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1067551C (en) * | 1998-01-04 | 2001-06-27 | 刘荣秀 | Preparation of high-immunity pig-sourced serum resisting main infectious diseases of chicken |
CN100541201C (en) * | 2005-02-01 | 2009-09-16 | 上海市血液中心 | The dilution mother liquor of glutamic-pyruvic transaminase quality control product |
CN101930009A (en) * | 2009-11-19 | 2010-12-29 | 首都医科大学附属北京朝阳医院 | Serum calcium standard substance |
CN101930009B (en) * | 2009-11-19 | 2013-09-11 | 首都医科大学附属北京朝阳医院 | Serum calcium standard substance |
CN101762710A (en) * | 2010-01-26 | 2010-06-30 | 明德松 | Multinomial liquid quality control material and preparation method thereof |
CN101762710B (en) * | 2010-01-26 | 2013-08-21 | 明德松 | Multinomial liquid quality control material and preparation method thereof |
CN104062442A (en) * | 2014-07-02 | 2014-09-24 | 明德松 | Liquid quality control material with multiple autoantibodies and preparation method thereof |
CN104062442B (en) * | 2014-07-02 | 2016-03-16 | 明德松 | Liquid quality control thing with multinomial autoantibody and preparation method thereof |
CN108152519A (en) * | 2017-11-06 | 2018-06-12 | 宁波美康保生生物医学工程有限公司 | For the preparation method of the blood plasma quality-control product of centrifugal type microfludic chip quality control |
CN113959807A (en) * | 2021-10-26 | 2022-01-21 | 上海瀚诺威生物科技有限公司 | Preparation method of glycosylated hemoglobin calibration quality control product |
Also Published As
Publication number | Publication date |
---|---|
CN1054205C (en) | 2000-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cohn | The properties and functions of the plasma proteins, with a consideration of the methods for their separation and purification. | |
Wood et al. | The effect of serial therapeutic plasmapheresis on platelet count, coagulation factors, plasma immunoglobulin, and complement levels | |
US4158544A (en) | Process for preparing a biological composition for use as a reference control in diagnostic analysis | |
US7481941B2 (en) | Method for separating components from blood plasma | |
CA1142175A (en) | Fractionation of protein mixtures by salting out followed by dialysis treatment | |
US4386068A (en) | Antihemophilic factor concentrate and method for preparation | |
US3640896A (en) | Process for stabilizing fowl red blood cells | |
Sehgal et al. | Large-volume preparation of pyridoxylated hemoglobin with high P50 | |
CN1015512B (en) | Tangential flow affinity ultrafiltration | |
US4085095A (en) | Clottable fibrinogen free Factor VIII product and process | |
Cohn | Chemical, physiological, and immunological properties and clinical uses of blood derivatives | |
Cohn | The chemical specificity of the interaction of diverse human plasma proteins | |
Ralston | Proteins of the camel erythrocyte membrane | |
Bazilinski et al. | Inhibition of platelet function by uremic middle molecules | |
CN1149722A (en) | Multiple liquid quality control pig serum and preparing method | |
Huisman et al. | Studies on animal hemoglobins II. The influence of inorganic phosphate on the physico-chemical and physiological properties of the hemoglobin of the adult chicken | |
CN107540743A (en) | A kind of method that bilayer chromatography prepares human fibrinogen | |
Bidwell et al. | Experiments with factor VIII separated from fibrinogen by electrophoresis in free buffer film | |
Masri et al. | Studies on abnormal hemoglobins. XII. Terminal and free amino groups of various types of human hemoglobin | |
Scudder | STUDIES IN BLOOD PRESERVATION*: THE STABILITY OF PLASMA PROTEINS | |
EP0131579A1 (en) | Purification of antihemophilia factor viii by precipitation with zinc ions | |
CN106543283A (en) | Transferrinss and its production and use | |
EP1727553B1 (en) | Agent for substitution of blood plasma and a method of its production | |
Saxena et al. | Can storage of thawed cryoprecipitate be extended to more than six hours? | |
Van der Plas et al. | Preparation and physical characteristics of a hemoglobin solution modified by coupling to 2‐nor‐2‐formylpyridoxal 5 ‘‐phosphate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |